Abstract: Provided herein are analyzers as well as related methods for measuring both an absorbance and emission of a sample. The analyzer includes light sources for epi-illumination and transillumination of the sample, and detectors for measuring the intensities of excitation, emission, and transillumination light. A dichroic mirror permits a portion of the excitation light to transmit to a detector that monitors changes in excitation light intensity. Temperature sensors allow for signal corrections based on temperature variations of the detectors and sample.

Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.

Abstract: A three-way catalyst article, and its use in an exhaust system for internal combustion engines, is disclosed. The catalyst article for treating exhaust gas comprising: a substrate; and a single catalyst layer deposited directly on the substrate; wherein the single catalyst layer comprises a first platinum group metal (PGM) component, an oxygen storage component (OSC) material, and an inorganic oxide; and wherein the single catalyst layer has a total washcoat loading of less than 2.4 g/in3.

Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.

Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.

Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.

Abstract: of analytes in a serum sample from a patient, and applying a mathematical algorithm to the expression levels, thereby producing a Mucosal Healing Index score for the patient. The present disclosure also provides kits that include two or more binding partners, each or which is capable of binding a different analyte measured in the disclosed mucosal healing assessment methods.

Abstract: Provided herein are assay cuvettes as well as related kits and methods for storing and transporting multiple solid reagents, and for performing diagnostic assays using the reagents held therein. The solid reagents are constrained within separate containers inside a lid of the cuvette. The containers are open to the inner chamber of the cuvette such that, when liquid buffer, reagent, or sample solutions is added to the cuvette, the solid reagents can be dissolved in the liquid to create within the cuvette a mixture that can then be assayed.

Abstract: Provided herein are analyzers as well as related methods for measuring both an absorbance and emission of a sample. The analyzer includes light sources for epi-illumination and transillumination of the sample, and detectors for measuring the intensities of excitation, emission, and transillumination light. A dichroic mirror permits a portion of the excitation light to transmit to a detector that monitors changes in excitation light intensity. Temperature sensors allow for signal corrections based on temperature variations of the detectors and sample.

Abstract: The present invention provides cryptates with excellent fluorescent properties. The cryptates are useful in biological assays and methods for the detection and identification of various analytes.

Abstract: A three-way catalyst article, and its use in an exhaust system for internal combustion engines, is disclosed. The catalyst article for treating exhaust gas comprising: a substrate; and a catalytic region on the substrate; wherein the catalytic region comprises a first platinum group metal (PGM) component, an oxygen storage component (OSC) material, a rare earth metal oxide, and an inorganic oxide; and wherein the rare earth metal oxide has an average diameter (d50) of more than 100 nm.

Abstract: A three-way catalyst article, and its use in an exhaust system for internal combustion engines, is disclosed. The catalyst article for treating exhaust gas comprising: a substrate; and a single catalyst layer deposited directly on the substrate; wherein the single catalyst layer comprises a first platinum group metal (PGM) component, an oxygen storage component (OSC) material, and an inorganic oxide; and wherein the single catalyst layer has a total washcoat loading of less than 2.4 g/in3.

Abstract: Among other things, an integrated portable energy conversion mat is to be installed at a pavement surface over which a car or truck is to pass. The mat has a width at least as wide as the distance between the outermost edges of the treads of the tires located at an axle of the car or truck. The mat has a top surface over which the tires of the car or truck are to pass. The mat includes a sealed enclosed space housing and energy conversion system. The energy conversion system includes two sets of channels that extend along a length of the mat and contain hydraulic fluid under pressure. An energy converter converts energy carried by the hydraulic fluid in response to the tires of the car or truck passing over the top surface into electrical energy. An electrical port is coupled to the energy converter and exposed at an outer surface of the mat.

Abstract: Disclosed are a method and/or a system of insurance rate optimization through driver behavior which includes a computer server of the driver monitoring environment to determine if a newly insured driver operating a private vehicle is adhering to a set of parameters set by an entity i.e. a driving school, an insurance provider and/or a family member of the newly insured driver. The system assigns a credit to the newly insured driver when it adheres to the set of parameters. The newly insured driver is monitored by the entity. A metadata is generated which includes a behavioral trait of the newly insured driver and an insurance rate is set through the insurance provider based on an adherence to the set of parameters set by the entity.

Abstract: The present invention provides 2,6,7 substituted purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

Abstract: The present invention provides substituted pyrrolopyrimidines of Formula I as described herein or a pharmaceutically acceptable salt or solvate thereof: The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

Abstract: The present invention provides 2,6,7,8 Substituted Purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

Abstract: Methods for managing content within an interactive augmented reality environment are described. An augmented reality environment may be provided to an end user of a head-mounted display device (HMD) in which content (e.g., webpages) may be displayed to the end user using one or more curved slates that are positioned on a virtual cylinder that appears body-locked to the end user. The virtual cylinder may be located around the end user with the end user positioned in the middle of the virtual cylinder such that the one or more curved slates appear to be displayed at the same distance from the end user. The position and size of each of the one or more curved slates may be controlled by the end user using head gestures and a virtual pointer projected onto the virtual cylinder.

Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.